1.Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”
Dorothy Cheuk-Yan YIU ; Huapeng LIN ; Vincent Wai-Sun WONG ; Grace Lai-Hung WONG ; Ken LIU ; Terry Cheuk-Fung YIP
Clinical and Molecular Hepatology 2024;30(4):970-973
2.Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”
Dorothy Cheuk-Yan YIU ; Huapeng LIN ; Vincent Wai-Sun WONG ; Grace Lai-Hung WONG ; Ken LIU ; Terry Cheuk-Fung YIP
Clinical and Molecular Hepatology 2024;30(4):970-973
3.Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”
Dorothy Cheuk-Yan YIU ; Huapeng LIN ; Vincent Wai-Sun WONG ; Grace Lai-Hung WONG ; Ken LIU ; Terry Cheuk-Fung YIP
Clinical and Molecular Hepatology 2024;30(4):970-973
4.Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”
Dorothy Cheuk-Yan YIU ; Huapeng LIN ; Vincent Wai-Sun WONG ; Grace Lai-Hung WONG ; Ken LIU ; Terry Cheuk-Fung YIP
Clinical and Molecular Hepatology 2024;30(4):970-973
Result Analysis
Print
Save
E-mail